EpiVax will be joining more than 1,400 companies from over 45 countries at Bio-Europe Spring, the premier springtime partnering conference bringing together a “whoʼs who” from biotech, pharma and finance in Europe’s most innovative biopharma clusters. Partner with us to hear about our new immunoinformatics platform accelerating the advancement of personalized cancer vaccine design. Partnering is ...

September 6, 2016 (Providence, RI) – EpiVax, Inc., “immune engineering” pioneer, has won a new $600,000 National Institutes of Health grant under the Small Business Innovation Research (SBIR) program to improve a vaccine for the problematic H7N9 avian influenza virus. The vaccine development program will be directed by Annie De Groot, M.D., EpiVax CEO/CSO, and Lenny Moise, Ph.D., EpiVax ...

Platine and EpiVax are co-organizing their 2nd seminar on Immunogenicity and Tolerance on October 24th, 2016. The conference agenda is shown below. Click this link to register This meeting will focus on the determinants of immunogenicity – a key feature of effective vaccines and a key barrier to success in the clinic for protein therapeutics. Conversely, tolerance induction is a key feature of successful protein therapeutics, ...

Standards of excellence. Models of advocacy. An unparalleled ability to succeed. These are characteristics of the vaccine industry’s top achievers. Last night at the 9th Vaccine Industry Excellence (ViE) Awards, winners were recognized for their outstanding contributions to the vaccine industry over the past 12-months. EpiVax’s own Annie De Groot took home Biotech CEO of the Year, and she is in good company – Sanofi ...

https://www.aaps.org/nationalbiotech/

We’re off to Stockholm for BIO-Europe Spring (BES2016), which will take place 4–6 April in Stockholm, Sweden. We will be joining international leaders from biotech, pharma and finance to identify and enter new strategic relationships. Sign up to meet us now through the partnering system or via email

Lucky us! the 13th International Bio Asia Conference is scheduled for March 15-16, 2016 at the Grand Hyatt, Tokyo in Roppongi. It might be a bit early for cherry blossoms, but hope springs eternal! We will be arriving a bit early and staying a bit late. Please let us know if you would like us to meet with you ...

As a Valentine’s day gift to women at risk of Zika everywhere, we’re providing access to our initial analysis of Zika and our opinion on Zika vaccine design.  If you just want access to the slides, here they are: https://bit.ly/Zika_Slides_EpiVax_2016 What’s the key point of this post? We think that it’s won’t be so easy to make an effective Zika vaccine. Rushing ...

The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...

The fact that we (EpiVax folk) haven’t said much about Zika probably has people scratching their heads. Well … here you have it We say: proceed with caution. Why? Zika is a Flavivirus, and that means it’s an RNA virus. That means lots of rapid evolution (the virus changes rapidly over time) and that has proven to be ...

(This post has been corrected, thanks Sebastian!) I love “Google Alerts”. They let me know when someone has just published an article citing one of our articles, and link me to new, exciting work that has just been made available on the web. Last week, my google alert linked me to a new paper by Sebastian Spindeldreher’s ...

Our latest mini-publication on ‘vaccines on demand’ can be found here: IQT Quarterly Winter 2016 – EpiVax

Sancha Salgueiro! Congratulations to Sancha and the team at ExpreS2ion Biotechnologies! https://www.linkedin.com/in/sanchasalgueiro

Graduate student Lu He, working with EpiVax CEO De Groot and collaborator Chris Bailey Kellog, recently reported that bacteria ‘copy and paste’ sequences from the human genome to escape immune response. She calls this escape mechanism “bacterial immune camouflage“. She used the JanusMatrix tool to develop a new measure of immune escape,  the Janus Immunogenicity Score ...

An academic version of this blog post, that explains why epitope redundancy provides resiliency (to bacteria) and weakness (to immune defense) can be found here.  . . . So a guy named Elledge has discovered a way to test your blood for the viruses that you’ve been exposed to. Sounds as if it will soon be available ...